Long-term	long-term	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
failed	failed	O	O	O	O
to	to	O	O	O	O
protect	protect	O	O	O	O
against	against	O	O	O	O
peripheral	peripheral	O	O	OTHERS	I
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Toxic	toxic	O	O	O	O
peripheral	peripheral	O	DISEASE	OTHERS	I
neuropathy	neuropathy	O	DISEASE	OTHERS	I
is	is	O	O	O	O
still	still	O	O	O	O
a	a	O	O	O	O
significant	significant	O	O	O	O
limiting	limiting	O	O	O	O
factor	factor	O	O	O	O
for	for	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
with	with	O	O	O	O
paclitaxel	paclitaxel	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
PAC	pac	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
its	its	O	O	O	O
closely	closely	O	O	O	O
related	related	O	O	O	O
amino	amino	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
glutamine	glutamine	O	O	OTHERS	I
were	were	O	O	O	O
claimed	claimed	O	O	O	O
to	to	O	O	O	O
ameliorate	ameliorate	O	O	O	O
PAC	pac	CHEMICALS	O	OTHERS	I
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
pilot	pilot	O	O	O	O
trial	trial	O	O	O	O
aimed	aimed	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
for	for	O	O	O	O
preventing	preventing	O	O	O	O
PAC-induced	pac-induced	O	O	O	O
peripheral	peripheral	O	DISEASE	OTHERS	I
neuropathy	neuropathy	O	DISEASE	OTHERS	I
in	in	O	O	O	O
a	a	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
double-blinded	double-blinded	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
electro-diagnostic	electro-diagnostic	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Forty-three	forty-three	O	O	O	O
ovarian	ovarian	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
were	were	O	O	O	O
available	available	O	O	O	O
for	for	O	O	O	O
analysis	analysis	O	O	O	O
following	following	O	O	O	O
six	six	O	O	O	O
cycles	cycles	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
PAC-containing	pac-containing	O	O	O	O
regimen	regimen	O	O	O	O
:	:	O	O	O	O
23	23	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
supplemented	supplemented	O	O	O	O
by	by	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
all	all	O	O	O	O
along	along	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
daily	daily	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
three	three	O	O	O	O
times	times	O	O	O	O
500	500	O	O	O	O
mg	mg	O	O	OTHERS	I
(	(	O	O	O	O
group	group	O	O	O	O
G	g	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
20	20	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
a	a	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
group	group	O	O	O	O
P	p	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
by	by	O	O	O	O
neurological	neurological	O	O	O	O
examinations	examinations	O	O	O	O
,	,	O	O	O	O
questionnaires	questionnaires	O	O	O	O
and	and	O	O	O	O
sensory-motor	sensory-motor	O	O	O	O
nerve	nerve	O	O	O	O
conduction	conduction	O	O	O	O
studies	studies	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
significant	significant	O	O	O	O
difference	difference	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
signs	signs	O	O	O	O
or	or	O	O	O	O
symptoms	symptoms	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
two	two	O	O	O	O
groups	groups	O	O	O	O
although	although	O	O	O	O
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
symptoms	symptoms	O	O	O	O
presented	presented	O	O	O	O
mostly	mostly	O	O	O	O
with	with	O	O	O	O
lower	lower	O	O	O	O
scores	scores	O	O	O	O
of	of	O	O	O	O
severity	severity	O	O	O	O
in	in	O	O	O	O
group	group	O	O	O	O
G.	g.	O	O	O	O
However	however	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
difference	difference	O	O	O	O
reached	reached	O	O	O	O
statistical	statistical	O	O	O	O
significance	significance	O	O	O	O
only	only	O	O	O	O
with	with	O	O	O	O
regard	regard	O	O	O	O
to	to	O	O	O	O
reported	reported	O	O	O	O
pain	pain	O	DISEASE	OTHERS	I
sensation	sensation	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
=	=	O	O	O	O
0.011	0.011	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Also	also	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
abnormal	abnormal	O	O	O	O
electro-diagnostic	electro-diagnostic	O	O	O	O
findings	findings	O	O	O	O
showed	showed	O	O	O	O
similarity	similarity	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
two	two	O	O	O	O
groups	groups	O	O	O	O
(	(	O	O	O	O
G	g	O	O	O	O
:	:	O	O	O	O
7/23	7/23	O	O	O	O
=	=	O	O	O	O
30.4	30.4	O	O	O	O
%	%	O	O	O	O
;	;	O	O	O	O
P	p	O	O	OTHERS	I
:	:	O	O	O	O
6/20	6/20	O	O	O	O
=	=	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
pilot	pilot	O	O	O	O
study	study	O	O	O	O
leads	leads	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
conclusion	conclusion	O	O	O	O
that	that	O	O	O	O
glutamate	glutamate	CHEMICALS	O	OTHERS	I
supplementation	supplementation	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
chosen	chosen	O	O	O	O
regimen	regimen	O	O	O	O
fails	fails	O	O	O	O
to	to	O	O	O	O
protect	protect	O	O	O	O
against	against	O	O	O	O
peripheral	peripheral	O	O	OTHERS	I
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
of	of	O	O	O	O
PAC	pac	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

